Abacavir (ABC) is the most powerful nucleoside analog reverse transcriptase inhibitor (NARTI) used to treat HIV and AIDS. It is available under the trade name Ziagen™ (GlaxoSmithKline} and the combination drugs Trizivir™(abacavir, zidovodine and lamivudine) and Kivexa®/Epzicom™(abacavir and lamivudine) . It has been well tolerated; its main side effect being hypersensitivity reactions, which can be dangerous or even (in some rare cases) fatal. Fortunately, genetic testing can indicate beforehand whether an individual will be hypersensitive; over 90% of patients can safely take abacavir.
Viral strains that are resistant to zidovudine (AZT) or lamivudine (3TC) are generally sensitive to abacavir, whereas strains that are resistant to AZT and 3TC are not as sensitive to abacavir. __NOTOC__
Abacavir is given orally and has a high bio-availability (83%). It is metabolised primarily through alcohol dehydrogenase or gluconyl transferase.
Abacavir should always be used in combination with other antiretroviral agents. Abacavir should not be added as a single agent when antiretroviral regimens are changed due to loss of virologic response.
This article is licensed under the GNU Free Documentation License.
It uses material from the
"Abacavir".
Home Page • arts • business • computers • games • health • hospitals • home • kids & teens • news • physicians • recreation• reference • regional • science • shopping • society • sports • world